Skip to main content
Erschienen in: Heart and Vessels 10/2016

29.01.2016 | Case Report

JAK2 mutation and acute coronary syndrome complicated with stent thrombosis

Erschienen in: Heart and Vessels | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Acute coronary syndrome (ACS) could be a precious opportunity for patients to reveal concealed diseases other than conventional risk factors for ACS, such as hypertension, dyslipidemia, diabetes mellitus, etc. In the setting of ACS, the intracoronary and systemic prothrombotic environment has led to an increase in the risk of stent thrombosis of which mortality was higher among patients with ACS, especially with the highest mortality in patients with ST elevation myocardial infarction. The some specific conditions which were concealed beyond the cardiovascular pathophysiology except well-known risk factors for ACS and stent thrombosis might involve the onset of ACS. We describe a case of a 64-year-old man who was admitted to intensive care unit for chest pain. This case found the possibility that polycythemia vera with Janus kinase 2 (JAK2) V617F mutation might be a underlying disease of ACS with stent thrombosis, and highlighted the importance of recognizing polycythemia vera with JAK2 V617F mutation as concealed disease for cardiologists. We would like to report and review the relationship between ACS and polycythemia vera with JAK2 V617F mutation.
Literatur
1.
Zurück zum Zitat Lazzeri C, Valente S, Chiostri M, Attana P, Mattesini A, Nesti M, Gensini GF (2014) Hyperglycemia, acute insulin resistance, and renal dysfunction in the early phase of ST-elevation myocardial infarction without previously known diabetes: impact on long-term prognosis. Heart Vessels 29:769–775CrossRefPubMed Lazzeri C, Valente S, Chiostri M, Attana P, Mattesini A, Nesti M, Gensini GF (2014) Hyperglycemia, acute insulin resistance, and renal dysfunction in the early phase of ST-elevation myocardial infarction without previously known diabetes: impact on long-term prognosis. Heart Vessels 29:769–775CrossRefPubMed
2.
Zurück zum Zitat Mrdovic I, Savic L, Lasica R, Krljanac G, Asanin M, Brdar N, Djuricic N, Cvetinovic N, Marinkovic J, Perunicic J (2013) Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart Vessels 28:424–433CrossRefPubMed Mrdovic I, Savic L, Lasica R, Krljanac G, Asanin M, Brdar N, Djuricic N, Cvetinovic N, Marinkovic J, Perunicic J (2013) Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart Vessels 28:424–433CrossRefPubMed
3.
Zurück zum Zitat Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061CrossRefPubMed Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061CrossRefPubMed
4.
5.
Zurück zum Zitat Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (2014) Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 92:289–297CrossRefPubMed Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (2014) Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 92:289–297CrossRefPubMed
6.
7.
Zurück zum Zitat Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122:2176–2184CrossRefPubMed Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122:2176–2184CrossRefPubMed
8.
Zurück zum Zitat (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med 123:656–664 (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med 123:656–664
9.
Zurück zum Zitat Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21:1952–1959CrossRefPubMed Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21:1952–1959CrossRefPubMed
10.
Zurück zum Zitat Shi K, Zhao W, Chen Y, Ho WT, Yang P, Zhao ZJ (2014) Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol 7:25CrossRefPubMedPubMedCentral Shi K, Zhao W, Chen Y, Ho WT, Yang P, Zhao ZJ (2014) Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol 7:25CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Lata K, Madiraju N, Levitt L (2010) JAK2 mutations and coronary ischemia. N Engl J Med 363:396–397CrossRefPubMed Lata K, Madiraju N, Levitt L (2010) JAK2 mutations and coronary ischemia. N Engl J Med 363:396–397CrossRefPubMed
12.
Zurück zum Zitat Vianello F, Cella G, Osto E, Ballin A, Famoso G, Tellatin S, Iliceto S, Cucchini U, Saggiorato G, Omenetto E, Tona F (2015) Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk? Am J Hematol 90:109–113CrossRefPubMed Vianello F, Cella G, Osto E, Ballin A, Famoso G, Tellatin S, Iliceto S, Cucchini U, Saggiorato G, Omenetto E, Tona F (2015) Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk? Am J Hematol 90:109–113CrossRefPubMed
13.
Zurück zum Zitat Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Mullauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874–1881CrossRefPubMedPubMedCentral Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Mullauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874–1881CrossRefPubMedPubMedCentral
Metadaten
Titel
JAK2 mutation and acute coronary syndrome complicated with stent thrombosis
Publikationsdatum
29.01.2016
Erschienen in
Heart and Vessels / Ausgabe 10/2016
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-016-0798-x

Weitere Artikel der Ausgabe 10/2016

Heart and Vessels 10/2016 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.